ArticleResuscitation plus2026
Vasopressin, steroids, and epinephrine in out-of-hospital cardiac arrest - a protocol for a randomized controlled trial (OHCA REVIVES trial).
Article in Resuscitation plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological mechanisms and clinical evidence of vasopressin, steroids, and epinephrine triple therapy in in-hospital cardiac arrest.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Several clinical trials have shown promising results for the vasopressin-steroid-epinephrine (VSE) triple therapy in patients experiencing in-hospital cardiac arrest (IHCA); however, this treatment strategy has not yet been studied in the prehospital setting. The OHCA REVIVES (A Randomized Clinical Trial of Patient Outcomes Following Out-of-Hospital Cardiac Arrest Receiving Epinephrine Versus In-together Vasopressin, Epinephrine, and Steroid) trial aims to evaluate the effectiveness of the VSE combined therapy in improving clinical outcomes in patients with out‑of‑hospital cardiac arrest (OHCA). Methods: The OHCA REVIVES trial is an investigator-initiated, multicenter, superiority cluster randomized controlled trial. Adult non-traumatic patients with OHCA treated by six participating advanced ambulance teams in Taipei and New Taipei City, Taiwan will be included. Biweekly randomized clusters of participating advanced ambulance teams were assigned to administer either VSE combined therapy or standard care during cardiac arrest. The primary outcome is sustained return of spontaneous circulation (ROSC ≥ 2 h), and key secondary outcomes include prehospital ROSC, survival to hospital discharge, and survival with favorable neurologic outcomes (cerebral performance category score ≤ 2) at hospital discharge. A total of 1344 patients will be included. Conclusion: The OHCA REVIVES trial is expected to provide new insights into pharmacological strategies for the treatment of OHCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.